Navigation Links
SARcode Bioscience Completes $44 Million Series B Financing
Date:7/18/2011

dry eye and diabetic macular edema. LFA-1 is member of the integrin family of adhesion receptors found on the surface of all leukocytes and represents a therapeutic target central to a number of inflammatory stimuli. SAR 1118 has demonstrated potency in blocking LFA-1 binding to its cognate ligand, intercellular adhesion molecule-1 (ICAM-1; CD54), thereby inhibiting cell adhesion, cytokine production, and cellular proliferation in in vitro models. In a Phase 2 trial, SAR 1118 demonstrated dose-dependent improvements in both signs and symptoms of dry eye.

About SARcode Bioscience

SARcode Bioscience, Inc., founded in 2006, is a venture-backed ophthalmic biopharmaceutical company based in Brisbane, CA.  SARcode's lead development program is a novel class of lymphocyte function-associated antigen-1 (LFA-1) antagonists for the treatment T-cell mediated inflammatory diseases.  Institutional investors include Alta Partners, Clarus Venture Partners, Rho Ventures and Sofinnova Ventures. www.sarcode.com.

About Sofinnova Ventures

Sofinnova Ventures has over 30 years of experience building life science corporate spin-outs and start-ups into market leaders. With $1 billion under management, the firm applies capital and expertise to guide companies to successful exits. Sofinnova's team of MDs and PhDs has significant scientific, operational and strategic experience, specializing in financing later stage clinical compounds. Sofinnova has offices in Menlo Park and La Jolla, California. www.sofinnova.com.

About Rho Ventures

Rho Ventures has a multi-stage investing strategy focused on high-growth companies in large markets. Rho Ventures' investments span new media, healthcare, IT, communications, energy technology and other disruptive technologies. Rho Ventures brings nearly 30 years of venture experience, combin
'/>"/>

SOURCE SARcode Bioscience, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine technology :

1. SARcode and Sunesis Announce Start of Phase 1 Clinical Trial in Ocular Inflammatory Diseases
2. SARcode Corporation Announces Phase 2 Study Results of SAR 1118 Topical Ophthalmic Solution for the Treatment of Dry Eye
3. Quinton Oswald Named Chief Executive Officer of SARcode Corporation
4. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
5. ImmuneRegen BioSciences, Inc. Demonstrates Radilex(TM) Increases Disease-Fighting White Blood Cells
6. Upstream Biosciences Acquires Innovative Platform Technology and Drug Candidates for Tropical Parasitic Diseases
7. Ardea Biosciences, Inc. Announces Completion of Phase 1 Clinical Trials of Novel Investigational HIV Drug RDEA806
8. Ardea Biosciences, Inc. Presents Results of Phase 1 Studies of RDEA806, a Novel NNRTI for HIV, at 47th ICAAC
9. Ardea Biosciences Lead MEK Inhibitor, RDEA119, to Enter Human Clinical Trials in Advanced Cancer Patients
10. Alacrity Biosciences Announces Positive Results from a Phase 2 Study of Its Dry Eye Treatment ALTY-0501
11. Sangamo BioSciences and Sigma-Aldrich Announce Nature Biotechnology Study Demonstrating Zinc Finger Technology for Modification of Human Stem Cells
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2015)... India , July 31, 2015 ... CRM solutions for video, data and cloud computing ... with a leading pharma giant for Internet of ... different IoT applications offered on subscription model. ... Pharma giant is striving for business innovations ...
(Date:7/30/2015)... July 30, 2015  ResMed Inc. (NYSE: RMD ... 30, 2015.  Revenue for the quarter was $453.1 million, ... June 30, 2014 (a 17 percent increase on a ... with the quarter ended June 30, 2014.  Diluted earnings ... the quarter ended June 30, 2014.  ...
(Date:7/30/2015)... BOTHELL, Wash. and VANCOUVER ... OGXI ) announced today that it will report ... 13, 2015. Company management will host a conference call ... provide an overview of financial results, clinical development programs ... access the webcast, log on to the Investor Relations ...
Breaking Medicine Technology:Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 2ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 3ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 4ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 5ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 6ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 7ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 8ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 9ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 10ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 11ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 12ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 13ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 14ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 15ResMed Inc. Announces Results for the Fourth Quarter and Fiscal Year 2015 16
... Denmark , Feb. 1 LEO Pharma ... mebutate) Gel, the company,s lead candidate for the topical treatment ... primary clinical endpoint of complete clearance of AK lesions in ... AK support results from the earlier REGION-I trial, a study ...
... Ill. and CASTRES, France , Feb. 1 ... licensing agreement with Pierre Fabre SA to develop and commercialize h224G11, ... (CIPF) in France and targeting the cMet receptor for ... progression of a range of solid tumors including, prostate, lung and ...
Cached Medicine Technology:LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 2LEO Pharma's PEP005 Meets Primary Endpoint in Phase III Trial for Pre-Cancerous Skin Condition 3Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 2Abbott and Pierre Fabre SA Announce Collaboration to Research and Develop Novel Treatments for Cancer 3
(Date:8/1/2015)... NY and Greenwich, CT (PRWEB) , ... August ... ... (“Professional”), a Great Point Partners I, L.P. (“GPP”) portfolio company has acquired Premier ... Connecticut — incorporating it into its portfolio of state-of-the-art clinics. , “Our acquisition ...
(Date:8/1/2015)... ... August 01, 2015 , ... BeverlyD, owner and founder of BeverlyD Luxe Organic ... very first small business donation to kick off the campaign for healing and Well-Being. ... legacy includes a complete line of raw, organic hair care products, as well as ...
(Date:7/31/2015)... Santa Rosa, CA (PRWEB) , ... July 31, ... ... been posted by High Times magazine. What are the STASH awards? The ... celebrate advances made by the cannabis-cultivation community as well as tried-and-true products that ...
(Date:7/31/2015)... ... 2015 , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) ... (GAPFON) 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central ... Cassiani, Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, ...
(Date:7/31/2015)... ... ... Precision Aesthetics is New York’s only Thermage skin tightening pinnacle and black diamond award ... fat reduction in New York. Due to its unparalleled level of experience for ... patients travel to New York to get their non-surgical skin tightening and body shaping ...
Breaking Medicine News(10 mins):Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:March4thforWellBeing Foundation Kickoff 2Health News:The High Times S.T.A.S.H. Awards Are in, Guess Who Took Home the Prize for “Best Grow System” 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4
... FORT WORTH, Texas, Nov. 11 Wound Management ... Management Technologies Division will search for partners to ... to develop opportunities within the International Biotechnology and ... developments concerning advisory board appointments, research affiliations, and ...
... FAIRFAX, Va.Catheter-directed therapy or catheter-directed thrombolysisan interventional radiology ... specially designed catheters to dissolve dangerous blood clots ... a first-line treatment option for massive pulmonary embolism, ... Vascular and Interventional Radiology . "Modern ...
... ... announces new research focusing on Employee Engagement, Revenue and the New Economy as kickoff ... ... 12, 2009 -- There is little else more pressing in business than the financial ...
... ... decades The American Red Cross is making available for sale to the ... and bound journals, antique uniforms (1925 – 1941), flags, vintage ... a model train, photographs (including those of the founder Clara Barton, past ...
... The Quigley Corporation, (Nasdaq: QGLY) , ... a conference call in which Ted Karkus, Chairman and CEO, will ... results and Q&A. , The conference call will be ... www.quigleyco.com ), at 11:00 AM (ET) on Thursday, November 12, ...
... , LONDON, Nov. 11 The healthcare market is ... the global economic slowdown. Costs for healthcare are reaching ... exception. Market players in this industry have been faced ... technological advancements in hardware, high replacement costs, exchange rates ...
Cached Medicine News:Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 2Health News:OTCBB-WNDM Announces Activation of BioPharma Division to Solicit Technology and Development Partners 3Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 2Health News:When seconds count: Interventional radiology treatment for pulmonary embolism saves lives 3Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 2Health News:Performance Connections International Announces New Research Focusing on the Impact of Employee Engagement in the New Economy 3Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 2Health News:American Red Cross Auctions Historical Artifacts Through OLS Trading, Inc 3Health News:The Quigley Corporation to Host Conference Call to Review Third Quarter Results and Provide Company Update 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 2Health News:Frost & Sullivan to Hold Analyst Briefing on the European Neurophysiological Monitoring Market, the Golden Standard in Patient Safety 3
The SF-3000 automated hematology analyzer can provide accurate and precise 23-parameter hematolgy results including a fully automated WBC 5-part differential from a compact space-save design....
Ac.T 5diff CP allows quick and direct access to a closed sample tubea feature that reduces manual sample handling, saves time and enhances safety by eliminating operators exposure to biohazards....
... 755 simplifies and automates high-volume ... automation and advanced technologies into ... accurate results every time. Plus, ... quality with its slide-on-slide smearing ...
... The CX31 continue ... of the CH2 microscopes ... arenas, now with UIS ... models improve all-around performance ...
Medicine Products: